% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Seifert:278400,
      author       = {U. Seifert$^*$ and A. Gafita and T. Telli$^*$ and A. Voter
                      and K. Herrmann$^*$ and M. Pomper and B. Hadaschik$^*$ and
                      S. P. Rowe and W. P. Fendler$^*$},
      title        = {{S}tandardized {PSMA}-{PET} {I}maging of {A}dvanced
                      {P}rostate {C}ancer.},
      journal      = {Seminars in nuclear medicine},
      volume       = {54},
      number       = {1},
      issn         = {0001-2998},
      address      = {Duluth, Minn.},
      publisher    = {Saunders},
      reportid     = {DKFZ-2023-01634},
      pages        = {60-68},
      year         = {2024},
      note         = {2024 Jan;54(1):60-68},
      abstract     = {Imaging of advanced prostate cancer is a challenging task,
                      as it requires longitudinal characterization of disease
                      extent in a standardized way to enable appropriate treatment
                      selection and evaluation of treatment efficacy. In the last
                      years, prostate-specific membrane antigen (PSMA)-PET/CT has
                      become the reference standard examination for patients with
                      advanced prostate cancer. Together with the rise of
                      PSMA-PET, standardized frameworks for the reporting of image
                      findings have been proposed, eg, the Prostate Cancer
                      Molecular Imaging Standardized Evaluation (PROMISE) and the
                      structured reporting system for PSMA targeted PET imaging
                      (PSMA-RADS) framework. Therefore, recent evidence on
                      PSMA-PET derived tumor volume as useful a biomarker for
                      outcome prognostication and related frameworks will be
                      discussed in the article. The PROMISE framework recommends
                      quantifying the tumor volume per-organ system, which
                      accounts for the fact that the location of the metastases
                      greatly influence its biological aggressiveness. In
                      addition, changes in PSMA-PET derived tumor volume have been
                      shown to be promising biomarkers for response assessment.
                      Limitations of PSMA-PET will also be discussed because the
                      tumor volume might not always be suited for response
                      assessment. As a pitfall of PSMA-based systems, decreasing
                      PSMA-expression might erroneously be interpreted as response
                      to therapy. Also, especially for patients with limited
                      disease, the tumor volume might not be ideal for response
                      assessment. Therefore, various frameworks have been
                      introduced to objectively measure response to therapy with
                      PSMA-PET. Amongst these, the PSMA-PET progression (PPP)
                      criteria and the response evaluation criteria in PSMA
                      (RECIP) are optimized for earlier and later phenotypes of
                      advanced prostate cancer, respectively. Variables needed to
                      determine PPP or RECIP outcome on PSMA-PET are recorded
                      under the umbrella of PROMISE recommendations. In this
                      article, various reporting and response assessment
                      frameworks are explained and discussed. Also, recent
                      evidence for the relevance of PSMA-PET biomarkers for
                      clinical management and outcome prognostication are shown.},
      subtyp        = {Review Article},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37573199},
      doi          = {10.1053/j.semnuclmed.2023.07.005},
      url          = {https://inrepo02.dkfz.de/record/278400},
}